share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  08/30 15:53
Moomoo AI 已提取核心訊息
On August 28, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, announced the successful closing of a public offering, which was upsized to $6.0 million. The offering included the sale of 53,558 American Depositary Shares (ADSs) and associated warrants, as well as pre-funded warrants to purchase additional ADSs. The ADSs and warrants were offered at a price of $1.00 per ADS, with the pre-funded warrants priced at $0.999 each. The warrants are exercisable immediately and will expire one year from the date of issuance, with an exercise price of £0.76 per ADS. The pre-funded warrants can be exercised at any time at a price of $0.001 per ADS. The offering was conducted under a registration statement on Form F-1, which was declared effective...Show More
On August 28, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, announced the successful closing of a public offering, which was upsized to $6.0 million. The offering included the sale of 53,558 American Depositary Shares (ADSs) and associated warrants, as well as pre-funded warrants to purchase additional ADSs. The ADSs and warrants were offered at a price of $1.00 per ADS, with the pre-funded warrants priced at $0.999 each. The warrants are exercisable immediately and will expire one year from the date of issuance, with an exercise price of £0.76 per ADS. The pre-funded warrants can be exercised at any time at a price of $0.001 per ADS. The offering was conducted under a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission (SEC) on the same day. TC BioPharm intends to use the net proceeds to support an upcoming clinical trial for Acute Myeloid Leukemia, increase market awareness, and cover operating expenses and working capital. The company specializes in developing allogeneic gamma-delta T cell therapies for cancer and other indications.
2024年8月28日，臨床階段生物製藥公司TC BioPharm (Holdings) PLC宣佈成功完成了一項公開發行，金額擴大到600萬美元。該發行包括銷售了53,558股美國存托股份（ADSs）及相關認股權證，以及預融資認股權證以購買額外的ADSs。ADSs和認股權證的發行價爲每股1.00美元，而預融資認股權證定價爲每股0.999美元。認股權證可立即行使，並將在發行日起一年內到期，行權價爲0.76英鎊每ADS。預融資認股權證可隨時以每股0.001美元的價格行使。該發行是在同一天由美國證券交易委員會（SEC）宣佈生效的F-1表格註冊聲明下進行的。TC BioPharm打算利用淨收益用於支持即將展開的急性髓系白血病臨床試驗，增加市場知名度，並支付營業費用和運營資金。該公司專注於開發用於癌症和其他適應症的同種異體γ-δ T細胞療法。
2024年8月28日，臨床階段生物製藥公司TC BioPharm (Holdings) PLC宣佈成功完成了一項公開發行，金額擴大到600萬美元。該發行包括銷售了53,558股美國存托股份（ADSs）及相關認股權證，以及預融資認股權證以購買額外的ADSs。ADSs和認股權證的發行價爲每股1.00美元，而預融資認股權證定價爲每股0.999美元。認股權證可立即行使，並將在發行日起一年內到期，行權價爲0.76英鎊每ADS。預融資認股權證可隨時以每股0.001美元的價格行使。該發行是在同一天由美國證券交易委員會（SEC）宣佈生效的F-1表格註冊聲明下進行的。TC BioPharm打算利用淨收益用於支持即將展開的急性髓系白血病臨床試驗，增加市場知名度，並支付營業費用和運營資金。該公司專注於開發用於癌症和其他適應症的同種異體γ-δ T細胞療法。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息